spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Attention Deficit Hyperactivity Disorder 

 HSMN NewsFeed - 21 Mar 2023
U.S. FDA Grants GrayMatters Health 510(k) Clearance to Market Prism for PTSD
Devices Neurology FDA
 HSMN NewsFeed - 2 May 2022
Supernus Announces FDA Approval of Qelbree(R) for the Treatment of ADHD in Adults
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Oct 2021
Tris Pharma(R) Hires Seasoned Business Development Executive
Biopharmaceuticals Generics Personnel
 HSMN NewsFeed - 21 Jul 2021
Corium Launches Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate) in the U.S. for Patients Age 6 Years and Older
Biopharmaceutical Neurology Product Launch
 HSMN NewsFeed - 12 Dec 2019
Lannett To Commence Marketing Generic Adderall(R) XR
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 17 Oct 2019
Teijin and NeuroSigma Enter into Exclusive License Agreement
Devices Neurology Licensing
 HSMN NewsFeed - 2 Oct 2019
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR(R) for the Treatment of Post-Surgical Pain
Biopharmaceuticals Drug Delivery Surgery FDA
 HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Jun 2019
DURECT Announces $15 Million Registered Direct Offering
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 25 Apr 2019
DURECT Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 27 Mar 2019
ANI Pharmaceuticals Announces Two Generic Product Launches
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Mar 2019
Lannett Enters Into Distribution Agreement For Generic Adderall(R)
Biopharmaceuticals Generics Distribution
 HSMN NewsFeed - 14 Feb 2019
SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Dec 2018
Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 10 Oct 2018
Tris Pharma Announces Hiring of Chief Commercial Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 30 Oct 2017
UCLA Team Reports Positive Topline Results from Double-Blind Trial of NeuroSigma's Non-Invasive eTNS System for Treatment of Pediatric ADHD
Devices Neurology
 HSMN NewsFeed - 10 Mar 2017
Tris Pharma Appoints New Chief Commercial Officer for Brand Business
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 3 Mar 2017
Otsuka Pharmaceutical to Acquire Neurovance, Inc.
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Feb 2016
Impax Receives FDA Approval for Generic Version of Adderall XR(R) (mixed salts of a single-entity amphetamine product) Capsules, CII
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 10 Feb 2016
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 2 Feb 2016
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Jan 2016
Neos Therapeutics Announces FDA Approval of Adzenys XR-ODT(TM) (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients 6 Years and Older
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 13 Jan 2014
Alcobra Strengthens Management Team With Addition of Industry Veteran David C. Baker as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Oct 2013
Par Pharmaceutical Begins Shipment of Generic Kapvay(R)
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 30 Jul 2013
Alcobra Ltd. Appoints Dr. Jonathan Rubin as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Oct 2012
Pfizer To Acquire NextWave Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Sep 2012
Impax Laboratories Announces Settlement of Litigation Relating to CONCERTA(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 10 Jan 2012
Shire Acquires US Rights to Resolor(R) (prucalopride)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Nov 2011
Shire Announces Strategic Partnership for ADHD Medicines in Japan With Shionogi & Co., Ltd.
Biopharmaceuticals
 HSMN NewsFeed - 6 Apr 2011
Shire Files Lawsuit Against Watson Pharmaceuticals, Inc. for Infringement of ADDERALL XR(R) Patents and for Breach of Contract
Biopharmaceuticals Litigation
 HSMN NewsFeed - 22 Mar 2011
Data Presented at AAAAI Annual Meeting Further Support the Safety and Efficacy of FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2011
FDA Approves INTUNIV(R) (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2011
Shire Files Complete Response to FDA's Not Approvable Letter for FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2011
NextWave Pharmaceuticals Secures $45 Million in Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Dec 2010
Shire Files Suit Against Impax and Watson
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 9 Sep 2010
Shire Expands Pipeline to Treat Orphan Muscle Diseases Through Collaboration With Acceleron Pharma
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Jul 2010
NovaVision's FDA-Cleared Visual Restoration Therapy (VRT) System and Company Assets Now Available
Devices
 HSMN NewsFeed - 8 Jul 2010
Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 26 Apr 2010
Mylan Begins Marketing First Generic Version of Desoxyn(R)
Biopharmaceuticals Generics
 HSMN NewsFeed - 23 Apr 2010
INTUNIV(TM) - Shire Files Suit Against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 13 Apr 2010
FDA Approves New Drug Application for PANCREAZE(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Feb 2010
Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2009
Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2009
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Oct 2009
FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Sep 2009
Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Aug 2009
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jul 2009
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2009
Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2009
Teva Introduces First Generic Adderall XR Capsules in the United States
Biopharmaceuticals Generics
 HSMN NewsFeed - 2 Apr 2009
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 31 Mar 2009
Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2009
Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 Mar 2009
Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 16 Mar 2009
Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 16 Mar 2009
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Mar 2009
Shire Announces Launch of FOSRENOL(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Feb 2009
UCB to divest Equasym(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 20 Feb 2009
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 9 Feb 2009
Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
Biopharmaceuticals Generics
 HSMN NewsFeed - 7 Oct 2008
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 25 Aug 2008
Noven Provides Update on Daytrana(R) Methylphenidate Transdermal System
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 9 Jun 2008
Noven Provides Update on Daytrana(TM) Methylphenidate Transdermal System
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 19 May 2008
Cortex Pharmaceuticals Announces Management Changes
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 23 Apr 2008
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2008
Cortex Receives Approval from German Regulatory Authority to Proceed with Two Clinical Trials for AMPAKINE(R) CX717 for the Acute Treatment of Respiratory Depression Due to Opiate Analgesics
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Jan 2008
Genizon BioSciences Secures $31 Million in Additional Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Jan 2008
FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Dec 2007
Cenomed BioSciences Announces Licensing Agreement with ThioPharma, Inc.
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 20 Nov 2007
Barr Confirms Patent Challenge of Focalin(R) XR
Biopharmaceuticals Generics
 HSMN NewsFeed - 26 Oct 2007
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Biopharmaceuticals
 HSMN NewsFeed - 25 Oct 2007
Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Shire Divests Non-Core Product Portfolio to Almirall
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 12 Sep 2007
Cortex Files AMPAKINE CX717 IND for ADHD
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 4 Sep 2007
Noven Provides Update on Daytrana(TM) Methylphenidate Transdermal System
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 27 Jul 2007
Shire's New ADHD Medication, VYVANSE(TM) (lisdexamfetamine dimesylate) Now Available in U.S. Pharmacies Nationwide
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2007
Cortex to Resume Clinical Trial with AMPAKINE(R) CX717 in Alzheimer-PET Scan Study after FDA Approves Protocol with Higher Doses of Drug
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Biopharmaceuticals
 HSMN NewsFeed - 19 May 2007
FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2007
Abraxis BioScience Announces Joint Venture With Cenomed for the Development of Novel Therapeutics for Neurological Diseases
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 May 2007
VYVANSE(TM) (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2007
Sciele Pharma to Acquire Alliant Pharmaceuticals, a Pediatric Specialty Pharmaceutical Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Mar 2007
Dr. Robert Langer Named as Chairman of Boston Life Sciences, Inc. Newly Formed Science and Technology Committee of the Board of Directors
Devices Personnel
 HSMN NewsFeed - 21 Mar 2007
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 2 Feb 2007
BioBehavioral Diagnostics Secures $8.5 Million Series A Financing
Diagnostics Venture Capital
 HSMN NewsFeed - 30 Jan 2007
Teva Receives Approval for Generic Focalin(TM) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 19 Jan 2007
Quest Diagnostics Announces Licensing Agreement for Genetic Testing Technology to Screen for Most Common Inherited Mental Impairment, Fragile X Syndrome
Diagnostics Licensing
 HSMN NewsFeed - 4 Jan 2007
Boston Life Sciences Acquires Rights to Develop and Commercialize Promising Phase II Spinal Cord Injury Drug, Cethrin(R), in Exclusive Worldwide License
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 22 Dec 2006
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2006
Shire Sues Andrx Pharmaceuticals, L.L.C.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2006
DOV Pharmaceutical, Inc. Announces New Strategic Direction, Bicifadine Clinical Studies Results and Program Updates
Biopharmaceuticals
 HSMN NewsFeed - 6 Oct 2006
New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Oct 2006
IMPAX Announces Dismissal of Lawsuit Related to Generic Concerta(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 28 Sep 2006
New Data for FTY720 -- Aiming to Become the First Orally Effective Multiple Sclerosis Treatment -- Show Sustained Benefits Over Two Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Sep 2006
Boston Life Sciences, Inc. Announces Findings from Review of POET-1 Study of ALTROPANE(R) Molecular Imaging Agent
Biopharmaceuticals Radiology Neurology
 HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2006
Shire's DAYTRANA(TM), First Transdermal Medication for Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children, Now Available in Pharmacies
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 27 Jun 2006
The U.S. Food and Drug Administration Approves Exelon(R) (rivastigmine tartrate) as the First Medication Indicated to Treat Parkinson's Disease Dementia
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Positive Study Results for DAYTRANA(TM) (methylphenidate transdermal system) Presented at a Major Medical Meeting
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 24 May 2006
UCB Completes Mutual Recognition Procedure for Equasym(TM) XL
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 May 2006
FDA Advisory Committee Recommends Approval of Exelon(R) (rivastigmine tartrate) in the Treatment of Dementia Associated with Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 May 2006
Athersys Announces Partnership With Angiotech to Commercialize Cell-Based Therapies for Cardiovascular Disease
Regenerative Medicine Cardiology
 HSMN NewsFeed - 11 May 2006
Boston Life Sciences, Inc. Solidifies Comprehensive Axon Regeneration Position with Children's Hospital Boston
Biopharmaceuticals Neurology Regenerative Medicine
Return to NewsFeed  

 Additional items found! 60

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 60 additional stories matching:
Attention Deficit Hyperactivity Disorder
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.